SCHEMBL3883113

SCHEMBL3883113

Cn1ncc2cc(-c3cc(CCC(=O)O)ccc3OCCc3cccc(F)c3)ccc21

nearest known ligand 0.48

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TP53 P04637 5/20 0.48
MDM2 Q00987 5/20 0.48
AR P10275 4/20 0.42
FFAR4 Q5NUL3 4/20 0.40
TGFBR1 P36897 1/20 0.40
NR3C1 P04150 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.40
CACNA1H O95180 1/20 0.39
FFAR1 O14842 1/20 0.38
TRPA1 O75762 1/20 0.38
CCNC P24863 1/20 0.38
CDK8 P49336 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3881559 0.93 TP53 (0.50) TP53MDM2ARFFAR4FFAR1
SCHEMBL3884003 0.93 TP53 (0.51) TP53MDM2ARFFAR4NR3C1
SCHEMBL3880605 0.90 TP53 (0.49) TP53MDM2FFAR4TGFBR1NR3C1
SCHEMBL3882096 0.88 FFAR4 (0.49) TP53MDM2ARFFAR4NR3C1
SCHEMBL3886022 0.88 TP53 (0.43) TP53MDM2ARFFAR4CACNA1H
SCHEMBL3883084 0.87 FFAR4 (0.46) TP53MDM2ARFFAR4TGFBR1
SCHEMBL3686723 0.86 FFAR4 (0.53) TP53MDM2ARFFAR4FFAR1
SCHEMBL3881173 0.86 RXRA (0.44) TP53MDM2ARFFAR4CACNA1H
SCHEMBL3882273 0.84 SLC16A3 (0.48) TP53MDM2ARFFAR4FFAR1
SCHEMBL3883139 0.84 AR (0.43) TP53MDM2ARFFAR4FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP claimed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US claimed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP claimed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US claimed
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP disclosed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US disclosed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP disclosed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof PTGER1, CYSLTR1, PTGS1 TP53 4018/4885MDM2 4035/4885AR 630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.